Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1974 Dec;77(3):520–538.

Leukotaxis and leukotactic disorders. A review.

P A Ward
PMCID: PMC1910939  PMID: 4611227

Full text

PDF
519

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alper C. A., Abramson N., Johnston R. B., Jr, Jandl J. H., Rosen F. S. Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3). N Engl J Med. 1970 Feb 12;282(7):350–354. doi: 10.1056/nejm197002122820701. [DOI] [PubMed] [Google Scholar]
  2. Alper C. A., Bloch K. J., Rosen F. S. Increased susceptibility to infection in a patient with type II essential hypercatabolism of C3. N Engl J Med. 1973 Mar 22;288(12):601–606. doi: 10.1056/NEJM197303222881204. [DOI] [PubMed] [Google Scholar]
  3. Altman L. C., Snyderman R., Oppenheim J. J., Mergenhagen S. E. A human mononuclear leukocyte chemotactic factor: characterization, specificity and kinetics of production by homologous leukocytes. J Immunol. 1973 Mar;110(3):801–810. [PubMed] [Google Scholar]
  4. BOYDEN S. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med. 1962 Mar 1;115:453–466. doi: 10.1084/jem.115.3.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Becker E. L., Ward P. A. Partial biochemical characterization of the activated esterase required in the complement-dependent chemotaxis of rabbit polymorphonuclear leukocytes. J Exp Med. 1967 Jun 1;125(6):1021–1030. doi: 10.1084/jem.125.6.1021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Berenberg J. L., Ward P. A. Chemotactic factor inactivator in normal human serum. J Clin Invest. 1973 May;52(5):1200–1206. doi: 10.1172/JCI107287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Boetcher D. A., Leonard E. J. Basophil chemotaxis: augmentation by a factor from stimulated lymphocyte cultures. Immunol Commun. 1973;2(4):421–429. doi: 10.3109/08820137309022813. [DOI] [PubMed] [Google Scholar]
  8. Bokisch V. A., Müller-Eberhard H. J., Cochrane C. G. Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med. 1969 May 1;129(5):1109–1130. doi: 10.1084/jem.129.5.1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Brier A. M., Snyderman R., Mergenhagen S. E., Notkins A. L. Inflammation and herpes simplex virus: release of a chemotaxis-generating factor from infected cells. Science. 1970 Dec 4;170(3962):1104–1106. doi: 10.1126/science.170.3962.1104. [DOI] [PubMed] [Google Scholar]
  10. Carruthers B. M. Leukocyte motility. II. Effect of absence of glucose in medium; effect of presence of deoxyglucose, dinitrophenol, puromycin, actinomycin D, and trypsin on the response to chemotactic substance; effect of segregation of cells from chemotactic substance. Can J Physiol Pharmacol. 1967 Mar;45(2):269–280. doi: 10.1139/y67-029. [DOI] [PubMed] [Google Scholar]
  11. Chang C., Houck J. C. Demonstration of the chemotactic properties of collagen. Proc Soc Exp Biol Med. 1970 May;134(1):22–26. doi: 10.3181/00379727-134-34719. [DOI] [PubMed] [Google Scholar]
  12. Clark R. A., Kimball H. R. Defective granulocyte chemotaxis in the Chediak-Higashi syndrome. J Clin Invest. 1971 Dec;50(12):2645–2652. doi: 10.1172/JCI106765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cohen S., Ward P. A. In vitro and in vivo activity of a lymphocyte and immune complex-dependent chemotactic factor for eosinophils. J Exp Med. 1971 Jan 1;133(1):133–146. doi: 10.1084/jem.133.1.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cohen S., Ward P. A., Yoshida T., Burek C. L. Biologic activity of extracts of delayed hypersensitivity skin reaction sites. Cell Immunol. 1973 Dec;9(3):363–376. doi: 10.1016/0008-8749(73)90051-8. [DOI] [PubMed] [Google Scholar]
  15. Cornely H. P. Reversal of chemotaxis in vitro and chemotactic activity of leukocyte fractions. Proc Soc Exp Biol Med. 1966 Jul;122(3):831–835. doi: 10.3181/00379727-122-31263. [DOI] [PubMed] [Google Scholar]
  16. DeMeo A. N., Andersen B. R. Defective chemotaxis associated with a serum inhibitor in cirrhotic patients. N Engl J Med. 1972 Apr 6;286(14):735–740. doi: 10.1056/NEJM197204062861401. [DOI] [PubMed] [Google Scholar]
  17. Estensen R. D., Hill H. R., Quie P. G., Gogan N., Goldberg N. D. Cyclic GMP and cell movement. Nature. 1973 Oct 26;245(5426):458–460. doi: 10.1038/245458a0. [DOI] [PubMed] [Google Scholar]
  18. Gallin J. I., Clark R. A., Kimball H. R. Granulocyte chemotaxis: an improved in vitro assay employing 51 Cr-labeled granulocytes. J Immunol. 1973 Jan;110(1):233–240. [PubMed] [Google Scholar]
  19. Gewurz H., Pickering R. J., Mergenhagen S. E., Good R. A. The complement profile in acute glomerulonephritis systemic lupus erythematosus and hypocomplementemic chronic glomerulonephritis. Contrasts and experimental correlations. Int Arch Allergy Appl Immunol. 1968;34(6):556–570. doi: 10.1159/000230149. [DOI] [PubMed] [Google Scholar]
  20. Goetzl E. J., Austen K. F. A method for assessing the in vitro chemotactic response of neutrophils utilizing 51cr-labeled human leukocytes. Immunol Commun. 1972;1(5):421–430. doi: 10.3109/08820137209022954. [DOI] [PubMed] [Google Scholar]
  21. Goetzl E. J., Austen K. F. Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors. J Clin Invest. 1974 Feb;53(2):591–599. doi: 10.1172/JCI107594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hill J. H., Ward P. A. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med. 1971 Apr 1;133(4):885–900. doi: 10.1084/jem.133.4.885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kaplan A. P., Goetzl E. J., Austen K. F. The fibrinolytic pathway of human plasma. II. The generation of chemotactic activity by activation of plasminogen proactivator. J Clin Invest. 1973 Oct;52(10):2591–2595. doi: 10.1172/JCI107451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kaplan A. P., Kay A. B., Austen K. F. A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med. 1972 Jan;135(1):81–97. doi: 10.1084/jem.135.1.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kay A. B., Austen K. F. Chemotaxis of human basophil leucocytes. Clin Exp Immunol. 1972 Aug;11(4):557–563. [PMC free article] [PubMed] [Google Scholar]
  26. Kay A. B., Stechschulte D. J., Austen K. F. An eosinophil leukocyte chemotactic factor of anaphylaxis. J Exp Med. 1971 Mar 1;133(3):602–619. doi: 10.1084/jem.133.3.602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Kay A. B. Studies on eosinophil leucocyte migration. II. Factors specifically chemotactic for eosinophils and neutrophils generated from guinea-pig serum by antigen-antibody complexes. Clin Exp Immunol. 1970 Nov;7(5):723–737. [PMC free article] [PubMed] [Google Scholar]
  28. Keller H. U., Sorkin E. Chemotaxis of leucocytes. Experientia. 1968 Jul 15;24(7):641–652. doi: 10.1007/BF02138287. [DOI] [PubMed] [Google Scholar]
  29. MCCLUSKEY R. T., BENACERRAF B., MCCLUSKEY J. W. STUDIES ON THE SPECIFICITY OF THE CELLULAR INFILTRATE IN DELAYED HYPERSENSITIVITY REACTIONS. J Immunol. 1963 Mar;90:466–477. [PubMed] [Google Scholar]
  30. Miller M. E., Nilsson U. R. A familial deficiency of the phagocytosis-enhancing activity of serum related to a dysfunction of the fifth component of complement (C5). N Engl J Med. 1970 Feb 12;282(7):354–358. doi: 10.1056/NEJM197002122820702. [DOI] [PubMed] [Google Scholar]
  31. Miller M. E., Oski F. A., Harris M. B. Lazy-leucocyte syndrome. A new disorder of neutrophil function. Lancet. 1971 Apr 3;1(7701):665–669. doi: 10.1016/s0140-6736(71)92679-1. [DOI] [PubMed] [Google Scholar]
  32. Mowat A. G., Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with rheumatoid arthritis. J Clin Invest. 1971 Dec;50(12):2541–2549. doi: 10.1172/JCI106754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Mowat A. G., Baum J. Polymorphonuclear leucocyte chemotaxis in patients with bacterial infections. Br Med J. 1971 Sep 11;3(5775):617–619. doi: 10.1136/bmj.3.5775.617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Mowat A., Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med. 1971 Mar 25;284(12):621–627. doi: 10.1056/NEJM197103252841201. [DOI] [PubMed] [Google Scholar]
  36. Ruddy S., Gigli I., Austen K. F. The complement system of man. 4. N Engl J Med. 1972 Sep 28;287(13):642–646. doi: 10.1056/NEJM197209282871306. [DOI] [PubMed] [Google Scholar]
  37. Smith C. W., Hollers J. C., Dupree E., Goldman A. S., Lord R. A. A serum inhibitor of leukotaxis in a child with recurrent infections. J Lab Clin Med. 1972 Jun;79(6):878–885. [PubMed] [Google Scholar]
  38. Snyderman R., Altman L. C., Frankel A., Blaese R. M. Defective mononuclear leukocyte chemotaxis: a previously unrecognized immune dysfunction. Studies in a patient with chronic mucocutaneous candidiasis. Ann Intern Med. 1973 Apr;78(4):509–513. doi: 10.7326/0003-4819-78-4-509. [DOI] [PubMed] [Google Scholar]
  39. Snyderman R., Gewurz H., Mergenhagen S. E. Interactions of the complement system with endotoxic lipopolysaccharide. Generation of a factor chemotactic for polymorphonuclear leukocytes. J Exp Med. 1968 Aug 1;128(2):259–275. doi: 10.1084/jem.128.2.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Snyderman R., Shin H. S., Hausman M. H. A chemotactic factor for mononuclear leukocytes. Proc Soc Exp Biol Med. 1971 Nov;138(2):387–390. doi: 10.3181/00379727-138-35903. [DOI] [PubMed] [Google Scholar]
  41. Snyderman R., Shin H., Dannenberg A. M., Jr Macrophage proteinase and inflammation: the production of chemotactic activity from the fifth complement by macrophage proteinase. J Immunol. 1972 Oct;109(4):896–898. [PubMed] [Google Scholar]
  42. Sorkin E., Stecher V. J., Borel J. F. Chemotaxis of leucocytes and inflammation. Ser Haematol. 1970;3(1):131–162. [PubMed] [Google Scholar]
  43. Stossel T. P. Phagocytosis (third of three parts). N Engl J Med. 1974 Apr 11;290(15):833–839. doi: 10.1056/NEJM197404112901506. [DOI] [PubMed] [Google Scholar]
  44. Tempel T. R., Snyderman R., Jordan H. V., Mergenhagen S. E. Factors from saliva and oral bacteria, chemotactic for polymorphonuclear leukocytes: their possible role in gingival inflammation. J Periodontol. 1970 Feb;41(2):71–80. doi: 10.1902/jop.1970.41.2.71. [DOI] [PubMed] [Google Scholar]
  45. Torisu M., Yoshida T., Ward P. A., Cohen S. Lymphocyte-derived eosinophil chemotactic factor. II. Studies on the mechanism of activation of the precursor substance by immune complexes. J Immunol. 1973 Nov;111(5):1450–1458. [PubMed] [Google Scholar]
  46. VOLKMAN A., GOWANS J. L. THE ORIGIN OF MACROPHAGES FROM BONE MARROW IN THE RAT. Br J Exp Pathol. 1965 Feb;46:62–70. [PMC free article] [PubMed] [Google Scholar]
  47. WARD P. A., COCHRANE C. G., MUELLER-EBERHARD H. J. THE ROLE OF SERUM COMPLEMENT IN CHEMOTAXIS OF LEUKOCYTES IN VITRO. J Exp Med. 1965 Aug 1;122:327–346. doi: 10.1084/jem.122.2.327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Walker W. S., Barlet R. L., Kurtz H. M. Isolation and partial characterization of a staphylococcal leukocyte cytotaxin. J Bacteriol. 1969 Mar;97(3):1005–1008. doi: 10.1128/jb.97.3.1005-1008.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Ward P. A. A plasmin-split fragment of C'3 as a new chemotactic factor. J Exp Med. 1967 Aug 1;126(2):189–206. doi: 10.1084/jem.126.2.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Ward P. A., Becker E. L. Biochemical demonstration of the activatable esterase of the rabbit netrophil involved in the chemotactic response. J Immunol. 1970 Nov;105(5):1057–1067. [PubMed] [Google Scholar]
  51. Ward P. A., Becker E. L. Mechanisms of the inhibition of chemotaxis by phosphonate esters. J Exp Med. 1967 Jun 1;125(6):1001–1020. doi: 10.1084/jem.125.6.1001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Ward P. A., Becker E. L. Potassium reversible inhibition of leukotaxis by ouabain. Life Sci. 1970 Mar 22;9(6):355–360. doi: 10.1016/0024-3205(70)90180-3. [DOI] [PubMed] [Google Scholar]
  53. Ward P. A., Becker E. L. The deactivation of rabbit neutrophils by chemotactic factor and the nature of the activatable esterase. J Exp Med. 1968 Apr 1;127(4):693–709. doi: 10.1084/jem.127.4.693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Ward P. A. Chemotaxis of human eosinophils. Am J Pathol. 1969 Jan;54(1):121–128. [PMC free article] [PubMed] [Google Scholar]
  55. Ward P. A. Chemotoxis of mononuclear cells. J Exp Med. 1968 Nov 1;128(5):1201–1221. doi: 10.1084/jem.128.5.1201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Ward P. A., Cohen S., Flanagan T. D. Leukotactic factors elaborated by virus-infected tissues. J Exp Med. 1972 May 1;135(5):1095–1103. doi: 10.1084/jem.135.5.1095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Ward P. A. Editorial: Dengue, complement and shock. N Engl J Med. 1973 Nov 8;289(19):1034–1035. doi: 10.1056/NEJM197311082891912. [DOI] [PubMed] [Google Scholar]
  58. Ward P. A., Lepow I. H., Newman L. J. Bacterial factors chemotactic for polymorphonuclear leukocytes. Am J Pathol. 1968 Apr;52(4):725–736. [PMC free article] [PubMed] [Google Scholar]
  59. Ward P. A. Leukotactic factors in health and disease. Am J Pathol. 1971 Sep;64(3):521–530. [PMC free article] [PubMed] [Google Scholar]
  60. Ward P. A., Offen C. D., Montgomery J. R. Chemoattractants of leukocytes, with special reference to lymphocytes. Fed Proc. 1971 Nov-Dec;30(6):1721–1724. [PubMed] [Google Scholar]
  61. Ward P. A., Remold H. G., David J. R. Leukotactic factor produced by sensitized lymphocytes. Science. 1969 Mar 7;163(3871):1079–1081. doi: 10.1126/science.163.3871.1079. [DOI] [PubMed] [Google Scholar]
  62. Ward P. A., Remold H. G., David J. R. The production by antigen-stimulated lymphocytes of a leukotactic factor distinct from migration inhibitory factor. Cell Immunol. 1970 Jul;1(2):162–174. doi: 10.1016/0008-8749(70)90003-1. [DOI] [PubMed] [Google Scholar]
  63. Ward P. A., Schlegel R. J. Impaired leucotactic responsiveness in a child with recurrent infections. Lancet. 1969 Aug 16;2(7616):344–347. doi: 10.1016/s0140-6736(69)92699-3. [DOI] [PubMed] [Google Scholar]
  64. Ward P. A., Talamo R. C. Deficiency of the chemotactic factor inactivator in human sera with 1 -antitrypsin deficiency. J Clin Invest. 1973 Feb;52(2):516–519. doi: 10.1172/JCI107209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Ward P. A., Zvaifler N. J. Quantitative phagocytosis by neutrophils. II. Release of the C5-cleaving enzyme and inhibition of phagocytosis by rheumatoid factor. J Immunol. 1973 Dec;111(6):1777–1782. [PubMed] [Google Scholar]
  66. Zigmond S. H., Hirsch J. G. Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor. J Exp Med. 1973 Feb 1;137(2):387–410. doi: 10.1084/jem.137.2.387. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES